bluebird bio 8-K Shows Celgene Amended Study Protocol For KarMMa Study Of bb2121 In Patients With Relapsed, Refractory Multiple Myeloma: Dose Range For Study Will Be 150-450 x 10^6 CAR+ T Cells, Enrollment Raised To Up To 140 Patients